Home Brain Tumors SISAQOL consortium – first international standards for quality of life measurement in...

SISAQOL consortium – first international standards for quality of life measurement in cancer clinical trials published in The Lancet Oncology

Cancer patients’ quality of life is becoming an increasingly important outcome in clinical trials. Known as patient-reported outcomes (PROs), factors such as symptoms, function, and other health-related quality-of-life aspects, provide essential information about measuring the clinical benefit of any given therapy. There is however no consensus on the optimal methods to  analyse PROs in cancer clinical trials.

Members of the SISAQOL consortium

A policy review paper, published in the February 2020 edition of The Lancet Oncology, has for the first time established International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials. A diverse panel of researchers and statisticians, key individuals from various international oncologic and medical societies, advisory and regulatory bodies, academic societies,…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Recent Comments